Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Homozygous GNAS 393C-allele carriers with locally advanced esophageal cancer fail to benefit from platinum-based preoperative chemoradiotherapy.

Alakus H, Bollschweiler E, Hölscher AH, Warnecke-Eberz U, Frazer KA, Harismendy O, Lowy AM, Mönig SP, Eberz PM, Maus M, Drebber U, Siffert W, Metzger R.

Ann Surg Oncol. 2014 Dec;21(13):4375-82. doi: 10.1245/s10434-014-3843-y. Epub 2014 Jul 2.

PMID:
24986238
2.

The GNAS1 T393C polymorphism predicts survival in patients with advanced squamous cell carcinoma of the larynx.

Lehnerdt GF, Franz P, Winterhoff S, Bankfalvi A, Grehl S, Lang S, Schmid KW, Siffert W, Jahnke K, Frey UH.

Laryngoscope. 2008 Dec;118(12):2172-6. doi: 10.1097/MLG.0b013e318185793ds.

PMID:
19029852
3.

Overall and relapse-free survival in oropharyngeal and hypopharyngeal squamous cell carcinoma are associated with genotypes of T393C polymorphism of the GNAS1 gene.

Lehnerdt GF, Franz P, Zaqoul A, Schmitz KJ, Grehl S, Lang S, Schmid KW, Siffert W, Jahnke K, Frey UH.

Clin Cancer Res. 2008 Mar 15;14(6):1753-8. doi: 10.1158/1078-0432.CCR-07-1605.

4.

Loss of Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy Predicts Postoperative Mortality in Esophageal Cancer Surgery.

Reisinger KW, Bosmans JW, Uittenbogaart M, Alsoumali A, Poeze M, Sosef MN, Derikx JP.

Ann Surg Oncol. 2015 Dec;22(13):4445-52. doi: 10.1245/s10434-015-4558-4. Epub 2015 Apr 17.

5.

Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.

Shridhar R, Hoffe SE, Almhanna K, Weber JM, Chuong MD, Karl RC, Meredith K.

Ann Surg Oncol. 2013 Sep;20(9):3038-43. doi: 10.1245/s10434-013-2988-4. Epub 2013 Apr 28.

PMID:
23625142
6.

The GNAS1 T393C single nucleotide polymorphism predicts the natural postoperative course of complete resected esophageal cancer.

Vashist YK, Kutup A, Musici S, Yekebas EF, Mina S, Uzunoglu G, Zehler O, Koenig A, Cataldegirmen G, Bockhorn M, Effenberger K, Kalinin V, Pantel K, Izbicki JR.

Cell Oncol (Dordr). 2011 Aug;34(4):281-8. doi: 10.1007/s13402-011-0016-x. Epub 2011 Feb 22.

PMID:
21340746
7.

Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer.

de Heer EC, Hulshoff JB, Klerk D, Burgerhof JGM, de Groot DJA, Plukker JTM, Hospers GAP.

Ann Surg Oncol. 2017 Jul;24(7):1811-1820. doi: 10.1245/s10434-017-5797-3. Epub 2017 Feb 10.

8.

Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.

Shridhar R, Freilich J, Hoffe SE, Almhanna K, Fulp WJ, Yue B, Karl RC, Meredith K.

Ann Surg Oncol. 2014 Nov;21(12):3744-50. doi: 10.1245/s10434-014-3795-2. Epub 2014 May 23.

PMID:
24854492
9.

Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer: Results From a Retrospective Multicenter European Study.

Mantziari S, Gronnier C, Renaud F, Duhamel A, Théreaux J, Brigand C, Carrère N, Lefevre JH, Pasquer A, Demartines N, Collet D, Meunier B, Mariette C; FREGAT working group – FRENCH – AFC.

Ann Surg. 2017 Nov;266(5):805-813. doi: 10.1097/SLA.0000000000002402.

PMID:
28742698
10.

The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.

Blackham AU, Yue B, Almhanna K, Saeed N, Fontaine JP, Hoffe S, Shridhar R, Frakes J, Coppola D, Pimiento JM.

J Surg Oncol. 2015 Nov;112(6):597-602. doi: 10.1002/jso.24050. Epub 2015 Sep 23.

PMID:
26394724
11.
12.

The impact of neoadjuvant chemoradiotherapy on perioperative outcomes, tumor pathology, and survival in clinical stage II and III esophageal cancer.

Markar SR, Bodnar A, Rosales J, Song G, Low DE.

Ann Surg Oncol. 2013 Nov;20(12):3935-41. doi: 10.1245/s10434-013-3137-9. Epub 2013 Jul 27.

PMID:
23892525
13.

Utility of restaging endoscopic ultrasound after neoadjuvant therapy for esophageal cancer.

Griffin JM, Reed CE, Denlinger CE.

Ann Thorac Surg. 2012 Jun;93(6):1855-9; discussion 1860. doi: 10.1016/j.athoracsur.2011.12.095. Epub 2012 Apr 18.

PMID:
22516835
14.

Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery.

Tu CC, Hsu PK, Chien LI, Liu WC, Huang CS, Hsieh CC, Hsu HS, Wu YC.

BMC Cancer. 2017 Jan 19;17(1):62. doi: 10.1186/s12885-017-3063-5.

15.

Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.

Castoro C, Scarpa M, Cagol M, Ruol A, Cavallin F, Alfieri R, Zanchettin G, Rugge M, Ancona E.

Ann Surg Oncol. 2011 Dec;18(13):3743-54. doi: 10.1245/s10434-011-1753-9. Epub 2011 May 10.

PMID:
21556952
16.

Esophageal adenocarcinoma stage III: Survival based on pathological response to neoadjuvant treatment.

Schwameis K, Zehetner J, Hagen JA, Oh DS, Worrell SG, Rona K, Cheng N, Samaan J, Green KM, Lipham JC.

Surg Oncol. 2017 Dec;26(4):522-526. doi: 10.1016/j.suronc.2017.10.001. Epub 2017 Oct 14.

PMID:
29113673
17.

Molecular Markers for the Prediction of Minor Response to Neoadjuvant Chemoradiation in Esophageal Cancer: Results of the Prospective Cologne Esophageal Response Prediction (CERP) Study.

Bollschweiler E, Hölscher AH, Herbold T, Metzger R, Alakus H, Schmidt H, Drebber U, Warnecke-Eberz U.

Ann Surg. 2016 Nov;264(5):839-846.

18.

Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.

Cho HJ, Kim YH, Kim HR, Kim DK, Park SI, Kim JH, Kim SB.

Ann Surg Oncol. 2015;22(6):1851-7. doi: 10.1245/s10434-014-4195-3. Epub 2014 Oct 25.

PMID:
25344308
19.

Treatment of clinical T2N0M0 esophageal cancer.

Hardacker TJ, Ceppa D, Okereke I, Rieger KM, Jalal SI, LeBlanc JK, DeWitt JM, Kesler KA, Birdas TJ.

Ann Surg Oncol. 2014 Nov;21(12):3739-43. doi: 10.1245/s10434-014-3929-6. Epub 2014 Jul 22.

PMID:
25047477
20.

Prognostic significance of lymphovascular invasion in patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.

Chen WH, Huang YL, Chao YK, Yeh CJ, Chang HK, Tseng CK, Liu YH.

Ann Surg Oncol. 2015 Jan;22(1):338-43. doi: 10.1245/s10434-014-3881-5. Epub 2014 Jul 15.

PMID:
25023545

Supplemental Content

Support Center